EE52 Cost-Minimisation Analysis of Ravulizumab Compared With Eculizumab in Patients With Atypical Hemolytic Uremic Syndrome (AHUS) in the Netherlands
| Verfasser: | |
|---|---|
| Dokumenttyp: | Artikel |
| Erscheinungsdatum: | 2022 |
| Reihe/Periodikum: | Value in Health ; volume 25, issue 12, page S63 ; ISSN 1098-3015 |
| Verlag/Hrsg.: |
Elsevier BV
|
| Schlagwörter: | Public Health / Environmental and Occupational Health / Health Policy |
| Sprache: | Englisch |
| Permalink: | https://search.fid-benelux.de/Record/base-27581485 |
| Datenquelle: | BASE; Originalkatalog |
| Powered By: | BASE |
| Link(s) : | http://dx.doi.org/10.1016/j.jval.2022.09.305 |
